Study Summary
This trial will test whether a new drug can slow down Alzheimer's disease.
- Dementia
- Alzheimer Disease
- Cognitive Decline
Treatment Effectiveness
Study Objectives
1 Primary · 21 Secondary · Reporting Duration: Baseline up to 4.5 years (End of treatment)
Trial Safety
Trial Design
2 Treatment Groups
JNJ-63733657
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
420 Total Participants · 2 Treatment Groups
Primary Treatment: JNJ-63733657 · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 24th, 2021
Last Reviewed: November 26th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Illinois | 100.0% |
What site did they apply to?
| Great Lakes Clinical Trials | 100.0% |
What portion of applicants met pre-screening criteria?
| Did not meet criteria | 100.0% |